Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Clostridium Stories

2012-12-03 08:27:30

JERSEY CITY, N.J., Dec. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the execution of an exclusive agreement with AstraZeneca to commercialize fidaxomicin tablets for the treatment of Clostridium difficile Infection (CDI) in South America, including Brazil, Central America, Mexico and the Caribbean. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Under the terms of the agreement AstraZeneca is responsible for the commercialization of...

2012-11-01 15:28:11

JERSEY CITY, N.J., Nov. 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Third Quarter 2012 Financial Highlights: DIFICID® gross sales in the U.S. and Canada of $18.7 million and net sales of $16.0 million, represent increases of 3.9% and 4.9% over the second quarter, respectively Estimated DIFICID ex-wholesaler...

2012-11-01 07:31:30

JERSEY CITY, N.J., Nov. 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the first patient has been dosed in its DEFLECT-1, Phase 3b clinical trial of DIFICID® (fidaxomicin) tablets for the prevention of Clostridium difficile-associated diarrhea (CDAD) in patients undergoing hematopoietic stem cell transplant (HSCT), often referred to as bone marrow transplantation. CDAD can be a serious complication of HSCT. (Logo:...

2012-10-15 07:29:30

SAN DIEGO, Oct. 15, 2012 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that new research findings for Clostridium difficile infection (CDI) and DIFICID® (fidaxomicin) tablets will be featured in presentations at IDWeek 2012 occurring October 17-21 in San Diego, CA. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Oral Presentations 692 - "Risk Factors for Recurrent Clostridium difficile Infection (CDI) Hospitalization among Hospitalized Patients...

2012-10-02 02:29:56

SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today the implementation of an initiative designed to accelerate and expand patient access to DIFICID® (fidaxomicin) tablets. Separately, and consistent with its goal of improving awareness and understanding of the disease, Optimer is also announcing a new project analyzing the burden of Clostridium difficile infection (CDI). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)...

2012-08-08 02:28:06

SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the Canaccord Genuity 32nd Annual Growth Conference on Tuesday, August 14 at 10:30 a.m. Eastern Time in Boston, MA., and provide a business overview and update. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com....

2012-08-02 02:30:46

SAN DIEGO, Aug. 2, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for DIFICID® tablets administered in the inpatient setting to treat Clostridium difficile-associated diarrhea (CDAD). Introduced in 2001, the CMS NTAP program is designed to support timely access of innovative therapies used to treat Medicare beneficiaries in the inpatient...

2012-07-18 10:18:05

A new study published today in PLoS Medicine re-evaluates the role of public reporting of hospital-acquired infection data. The study, conducted by Nick Daneman and colleagues, used data from all 180 acute care hospitals in Ontario, Canada. The investigators compared the rates of infection of Clostridium difficile colitis prior to, and after, the introduction of public reporting of hospital performance; public reporting was associated with a 26% reduction in C. difficile cases. The authors...

2012-07-16 23:00:45

The findings of the study published in July 2012 on The American Journal of Gastroenterology, revealed a 65% increase in the incidence of clostridium difficile-associated diarrhea (CDAD) among users of PPIs (Proton Pump Inhibitors), including Nexium. Nexium, manufactured by AstraZeneca, is a medication that people take to prevent on-going heartburn. In February 2012, the US FDA issued a drug safety communication notifying the public that the use of stomach acid drugs known as proton pump...

2012-07-12 06:21:47

OAKLAND, Calif., July 12, 2012 /PRNewswire-USNewswire/ -- Clorox Professional Products Company, a division of The Clorox Company (NYSE: CLX), announced today that Clorox Healthcare(TM) Bleach Germicidal Wipes are now registered by the U.S. Environmental Protection Agency (EPA) to kill Clostridium difficile (C. difficile) spores in three minutes, the fastest C. difficile contact time available for disinfecting wipes.[i] Clorox Healthcare(TM) Bleach Germicidal Wipes are now EPA-registered to...


Latest Clostridium Reference Libraries

0_d6572564d3305dc462f4641398789e11
2011-04-15 13:32:47

Clostridium botulinum is a gram-positive, rod-shaped bacterium that produces neurotoxins, known as botulinum neurotoxins types A-G, that cause the flaccid muscular paralysis seen in botulism. It is the main paralytic agent in botox and is commonly found in soil. It is also an obligate anaerobe, meaning oxygen is poisonous to the cells. Superoxide dismutase helps C. botulinum tolerate traces of oxygen. It was first recognized and isolated in 1895 by Emile van Ermengem. Subsequent outbreaks...

More Articles (1 articles) »